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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
A search was performed in the EMBASE, SciELO / LILACS, 
PubMed / Medline and Cochrane Library databases using the 
following words: gastroesophageal reﬂux, gerd, heartburn, 
nerd, gero, esophagus, esophagitis, extra-esophageal, 
asthma, atypical symptoms, chest pain, cough, globus 
sensations, hoarseness, otorhinolaryngology diseases, pain, 
respiratory tract diseases, laryngitis, anti-ulcer agents, 
enzyme inhibitors, proton pumps, lansoprazole, omeprazole, 
proton pump inhibitors, rabeprazole, continuous, on-demand, 
surgery, fundoplication, non acid*, alkaline, weakly acid*, 
gas, stomach diseases, stomach/pathology, Helicobacter, 
Helicobacter infections, burimamide, cimetidine, ebrotidine, 
etintidine, famotidine, lafutidine, loxtidine, metiamide, 
mifentidine, nizatidine, oxmetidine, ranitidine, ranitidine 
bismuth citrate, roxatidine acetate, tiotidine, zolantidine, 
histamine H2 antagonists, benzamides, dopamine antagonists, 
bromopride, domperidone metoclopramide, smoking, alcohol, 
obesity, weight loss, caffeine, coffee, citrus, chocolate, spicy 
food, head of bed elevation, late-evening meal, diet*, life 
style, body mass index, alcoholic, postprandial period, beer, 
wine, supine position, food*, eating, exercise, dietary ﬁber, 
dietary fats, beds*, bedding and linens*.
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A total of 5,000 publications were retrieved. Using the 
ﬁlters: humans, randomized controlled trial, randomized 
AND controlled AND trial, clinical AND trial, clinical trials, 
random*, random allocation, therapeutic use, epidemiologic 
methods, cohort studies, cohort AND stud*, prognos*, ﬁrst 
AND episode, cohort, we selected 73 studies to support 
this Guideline.
DEGREE OF RECOMMENDATION AND STRENGTH OF EVIDENCE
A: Experimental or observational studies of best 
consistency.
B: Experimental or observational studies of lower 
consistency.
C: Case reports (non-controlled studies).
D: Opinion without critical evaluation, based on 
consensuses, physiological studies or animal models.
OBJECTIVE
Due to high prevalence, variety of the clinical presenta-
tion forms and economic impact, consequences of loss of 
quality of life and clinical-laboratory research costs, the 
implementation of international consensus meetings has 
been encouraged. On the other hand, the diagnosis and 
therapeutic management of gastroesophageal reflux dis-
ease (GERD) has varied from center to center, which is an 
important factor in the search for scientific evidence on 
the issue, prompting the implementation of this Guideline, 
which seeks to answer four key clinical questions of the 
non-pharmacological treatment of GERD.
1. DOES THE NONPHARMACOLOGICAL TREATMENT PRODUCE 
RESULTS IN GERD?
OBESITY
Body mass index (BMI) > 25 is a risk factor for erosive 
GERD1 (B). There is an association between reflux symp-
toms and obesity (OR: 2.6)2 (B). BMI is associated with 
reflux (OR per 5 units: 1.9)3 (B). BMI > 25 is a risk fac-
tor (OR: 1.41) for GERD4 (B). Obesity is associated with 
GERD5 (B). Weight decrease does not reduce the mani-
festations of reflux6 (B). In patients with mean BMI of 
42.5 kg/m2, there is no association with the prevalence of 
GERD7 (B). Obesity predisposes to gastroesophageal re-
flux, and weight loss improves postprandial reflux and re-
duces pH time < 48 (B).
SMOKING
Smoking is a risk factor for non-erosive GERD1 (B) 
and for reflux symptoms2 (B). Smokers have more 
reflux episodes than nonsmokers, but a 24-hour 
abstinence does not reduce the pH time < 49 (B). 
24-hour smoking abstinence reduces the number of reflux 
episodes, but does not affect the total acid exposure10 (B). 
Individuals abstaining from smoking for 48 hours have in-
creased esophageal acid exposure11 (B). Smoking is associ-
ated with GERD5,12 (B).
ALCOHOL
Alcohol intake is a risk factor for erosive GERD1 (B). 
Frequent consumption of alcohol is a risk factor for re-
flux symptoms2 (B). The habits of drinking wine or beer 
increase the risk of reflux (NNH 7 to 9)13 (B). Alcohol 
consumption is a risk factor for erosive GERD (OR: 2.42 
to 2.85)4,5 (B).
COFFEE
Coffee consumption is associated with GERD (OR: 1.23)5(B).
DIET
The consumption of sweets and white bread is associated 
with symptoms of reflux2 (B). Fruit consumption has a 
protective effect on reflux symptoms2 (B). Protein intake is 
associated with erosive GERD, and fiber, with a lower risk 
of GERD14 (B). Excessive consumption of food and sweet 
food is associated with GERD5 (B). High-fat diet does not 
increase the number of reflux episodes, or acid esophageal 
exposure15 (B). 
POSTURE
Working in an inclined position is a risk factor for non-
erosive GERD1 (B). GERD episodes are triggered by pos-
ture5 (B).
INCLINED HEAD OF THE BED 
Sleeping with a wedge-shaped support is associated with 
less acid exposure than in the horizontal position16 (B). 
Raising the head of the bed (28 cm) reduces the number of 
reflux episodes and pH time < 517 (B).
NIGHT MEALS
The later the night the meal is, the higher the rate of reflux 
episodes, especially in obese individuals and in those with 
erosive GERD18 (B). Going to bed immediately after din-
ner is associated with increased risk of GERD, especially 
within a time period of less than 3 hours19 (B).
PHYSICAL EXERCISE
Physical activity seems to have a protective effect against 
GERD2 (B).
STRESS AND FATIGUE
GERD episodes are triggered by stress and fatigue11 (B). 
Stress is among the risk factors for GERD12 (B).
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RECOMMENDATION
Although obesity (BMI > 25), smoking, alcohol consump-
tion, coffee, sweets, proteins, excess food, inclined posture, 
stress and fatigue are associated with GERD, there is no 
consistent information to define that the resolution of 
these factors is followed by resolution or improvement 
of GERD. However, the elevation of the head of the bed 
and going to bed only after a minimum of three hours after 
the night meal are measures that reduce esophageal acid 
exposure. 
2. WHAT ARE THE INDICATIONS OF SURGICAL TREATMENT 
OF GERD?  
HIATAL HERNIA
PARAESOPHAGEAL
The laparoscopic Nissen fundoplication is equally effective 
in patients with GERD and paraesophageal hernia20 (B). 
There is improvement in abdominal pain, reflux, digestion 
score and quality of life score in patients with large para-
esophageal hernias submitted to laparoscopic surgery21 
(B). At the average follow-up period of 72 months, 93% of 
patients are free of GERD-related symptoms22 (B).
RISK FACTOR
Hiatal hernia is a risk factor for erosive GERD1 (B). A hia-
tal hernia < 3 cm is a risk factor for non-erosive GERD, 
and a hiatal hernia > 3 cm, for erosive GERD and Barrett’s 
esophagus23 (B). The size of hiatal hernia, low pressures 
in the lower esophageal sphincter, esophageal acid expo-
sure and number of reflux episodes are associated with 
esophagitis severity24 (B). Hiatal hernias > 2 cm are asso-
ciated with Barrett’s esophagus and erosive GERD25 (B). 
The presence of hiatal hernia is associated with more se-
vere esophagitis and predisposes patients with non-erosive 
GERD to more severe histological alterations26 (B). Patients 
with hiatal hernias have a high incidence of pathological 
reflux, regardless of the low pressure in the lower eso- 
phageal sphincter. Patients with pathologic reflux have 
esophageal propulsion failure and/or mechanical defects 
of the cardia associated with hiatal hernia27 (B).
PROGNOSIS
Recurrence after fundoplication (Nissen or Toupet) is 
higher in large hernias (grades 3 and 4)28 (B). The perma-
nent migration of the esophagogastric junction has more 
relevance in GERD prognosis than in sliding hiatal hernia, 
with reduction of the junction. Hiatal insufficiency and 
concentric hiatal hernia are determinant factors of irre-
versible cardia incontinence29 (B). In patients with GERD 
and hiatal hernia (31% erosive GERD and 75% lower 
sphincter dysfunction), reduction, crural closure, and Nis-
sen fundoplication result in symptom improvement, at a 
14-month follow-up30 (B). In patients with GERD (com-
plicated or not), the presence of hiatal hernia determines 
significant increase in the PPI dose to achieve intraesopha-
geal acid suppression31 (B).
RECOMMENDATION
Considering that:
The presence of the permanent migration of esopha-
gogastric junction and size of hiatal hernia (> 2 cm) are 
factors of worst prognosis for GERD;
The presence of hiatal hernia requires higher doses of 
PPIs;
The result of the laparoscopic fundoplication is ad-
equate, including for paraesophageal hernia.
Hiatal hernias associated with GERD, especially 
those > 2 cm and fixed, should be treated surgically.
MOTILITY
The Nissen fundoplication has good results in patients 
with normal esophageal motility, and the Toupet tech-
nique, in patients with esophageal dysmotility32 (B). 
There is no difference in postoperative symptoms in pa-
tients with or without esophageal dysmotility submitted 
to fundoplication (Nissen or Toupet)33 (A). The type of 
fundoplication should not be determined by the pres-
ence of dysmotility, as the postoperative dysphagia is 
not related to it34 (A). Preoperative dysmotility reflects 
a more severe disease, does not affect the postoperative 
outcomes, does not improve fundoplication and may oc-
cur after surgery35 (B).
RECOMMENDATION
Considering that:
The preoperative dysmotility reflects a more severe 
disease, does not affect the postoperative outcomes, does 
not improve with fundoplication and may occur after sur-
gery; no surgical treatment should be indicated using the 
parameter of esophageal dysmotility.
COST
From the perspective of the National Health System, lapa-
roscopic fundoplication is more cost-effective over eight 
years than PPI36 (B). Over five years, the cost of PPI is low-
er than the open surgery for GERD37 (B). Apparently, the 
Nissen fundoplication is more cost-effective in the treat-
ment of GERD than treatment with PPI38 (B). 
RECOMMENDATION 
Apparently, the laparoscopic Nissen fundoplication, from 
the perspective of the National Health System, is more cost 
effective than PPI therapy over eight years. However, this is 
not the case with open surgery. 
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3. WHEN SHOULD CLINICAL TREATMENT BE INDICATED 
VERSUS SURGICAL TREATMENT? 
In patients with GERD (erosive and non-erosive), antire-
flux surgery, compared to drug treatment with a PPI re-
duces the pH time < 4.0 and improves the VAS symptom 
score, the GERSS score, and scores of heartburn and re-
gurgitation39 (A).
In patients with chronic erosive GERD, the Nissen 
surgery, compared to the use of PPIs, improves symptom 
scores, including the digestive score, and reduces the pH 
time < 4.040 (A). 
In patients with chronic erosive reflux disease, Nissen 
surgery compared to PPI increases the degree of patient 
satisfaction (NNT 5)41 (A).
In patients with erosive reflux disease, antireflux sur-
gery (Nissen or Toupet) compared to omeprazole 20 mg 
daily reduces the risk of treatment failure over 5 years. 
There is a greater number of treatment failures over five 
years with clinical treatment of omeprazole 40 mg or 
60 mg compared to surgery (Nissen or Toupet). Surgery 
reduces the risk of treatment failure by 11.6% (95% CI: 
0.6-22.6) - NNT: 9. However, symptom scores (GSRS) and 
quality of life scores (PGWB) were similar in the two com-
pared forms of treatment42 (A).
In patients with chronic erosive reflux disease, antire-
flux surgery (Nissen or Toupet) in comparison to omepra-
zole 20 mg reduces treatment failure, and, maintained for 
seven years, reduces dysphagia (NNT 38) and hiatal hernia 
(NNT 2)43 (A). 
In patients with chronic GERD (reflux symptoms + 
esophagitis + previous treatment > 3 months), treatment 
with esomeprazole 20 mg or 40 mg is equivalent to lapa-
roscopic surgery (Nissen), with 93% and 90% of patients 
remaining in symptom remission, respectively 44 (A).
There is a greater number of therapeutic failures in 
three years with the clinical treatment of omeprazole 
40 mg or 60 mg, when compared to surgery (Nissen or 
Toupet). Surgery reduces the risk of treatment failure by 
12.9% (95% CI: 1.9-23.9) - NNT: 8. However, symptom 
scores (GSR) and quality of life (PGWB) were similar in 
the two forms of treatment45 (A). 
SYMPTOMS, ESOPHAGITIS AND PH
In patients with GERD not submitted to surgery, at a fol-
low-up of 17 to 22 years, symptoms improved in 70% and 
worsened in 20%. Of these patients, 66% developed ero-
sive GERD and/or pH changes, and 10% Barrett’s esopha-
gus46 (B).
At 12 months of follow-up, GERD treatment with 
medication and surgery (Nissen) is effective. However, 
surgery offers additional benefit to patients who had par-
tial improvement with medication at a mean follow-up of 
6.9 years41 (A).
At 18 months, regression from dysplasia to Barrett’s 
esophagus obtained with Nissen fundoplication (93.8%) is 
higher than that obtained with PPI (63.2%)47 (B).
The quality of life is higher in patients submitted to 
surgery compared to those undergoing medical treatment, 
at  12 months of follow-up48 (B).
The laparoscopic Nissen fundoplication leads to lower 
esophageal acid exposure in three months and better qual-
ity of life after 12 months, when compared to clinical treat-
ment40 (A).
Patients with Barrett’s esophagus have a 33% regression 
after antireflux surgery. The regression is more significant 
the longer the time after surgery49 (B).
PATIENT PREFERENCE
Laparoscopic surgery improves the quality of life of pa-
tients whose symptoms are adequately controlled with 
PPIs50 (B).
PROGNOSIS
In patients with GERD submitted to surgery after a fol-
low-up of 5.9 years, 37% were using medications (PPIs, 
H2 blockers or antacids), of which 17% had never stopped 
and 83% resumed after 2.5 years due to return of symp-
toms. The pH-metry was abnormal in 32%51 (B).
Comparing the response to surgical treatment of 
GERD, after 43 months, 66% had symptom improvement, 
which was lower in patients with non-erosive GERD52 (B).
After five years, there was no difference in symptom 
improvement, adverse effects, or quality of life scores 
among patients with erosive and non-erosive GERD who 
underwent laparoscopic Nissen fundoplication53 (B).
There was no difference in response rates among pa-
tients undergoing surgery for GERD with open or laparo-
scopic techniques, and this was higher in patients under-
going clinical treatment54 (B).
In two years, 14.5% of medically treated patients de-
veloped Barrett’s esophagus compared with no patients 
submitted to surgery55 (B).
Heartburn and esophagitis are effectively treated by 
medical and surgical therapy. Only surgery improved re-
gurgitation, dysphagia and esophageal motility56 (B).  
At 10.9 years of follow-up, the Nissen fundoplication 
produces 84% symptom resolution, 89% esophagitis reso-
lution and 5% use of medication, while the clinical treat-
ment produces, respectively, 53%, 45%, and 21%57  (B).
Laparoscopic fundoplication produces the same re-
sults in patients with erosive or nonerosive GERD, with 
symptom improvement and reduction in PPI use58 (B).
Patients with Barrett’s esophagus have a 33% regres-
sion after antireflux surgery. The regression is more sig-
nificant the longer the time after surgery49 (B). 
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LOWER ESOPHAGEAL SPHINCTER PRESSURE
In patients with erosive GERD treated with PPI, the 
rate of recurrence at 12 months was 7.7% when they 
had normal pressure of the lower esophageal sphincter 
(> 8 mmHg), 38.1% in those with sphincter dysfunction 
and preserved motility and 79.5% in those with sphinc-
ter dysfunction and dysmotility59 (B).
In five years of follow-up, patients with inadequate 
response to PPIs can benefit from laparoscopic fundo-
plication, especially regarding the improvement of the 
quality of life60 (B). 
During one year of follow-up, antireflux surgery 
obtained better results than medical treatment in rela-
tion to the symptoms of heartburn (19% versus 43%), 
regurgitation (8% versus 30%), increase in the need 
for PPIs (19% versus 74%), quality of life score (4 ± 0.6 
versus 21 ± 1.4); and patient satisfaction (21.6% versus 
5.9%)61 (B).
The success rate of Nissen fundoplication is 75.3%, 
and is associated with 77.1% of patients who responded to 
medical treatment and 56.0% who did not respond62 (B). 
STENOSIS
In two years of follow-up of patients with erosive GERD 
and stenosis, antireflux surgery reduces the number of 
dilations by a factor of 10, reduces the dysphagia score in 
50%, and 91.9% of patients were satisfied63 (B).
In a 10-year follow-up of patients that underwent 
Nissen fundoplication, the persistence or presence of 
symptoms was 32 %, and 68% were asymptomatic. The 
quality of life remained high, although 80% had to un-
dergo a new fundoplication procedure64 (B). 
NON-ACID GERD 
In patients on acid suppression, episodes of acid re- 
flux are not associated with symptoms, but with mixed 
reflux episodes (liquid-gas)65 (B).
When compared to healthy patients, the number of 
reflux events in 24 hours after fundoplication is signifi-
cantly lower. Most reflux episodes after surgery are non-
acid66 (B).
Most preoperative patients  had a positive symptom 
index, and 14 months after surgery, these patients were 
asymptomatic or had improved greatly67 (B).
Most patients undergoing prolonged PPI use, with 
persistent symptoms and a positive symptom index, 
have non-acid reflux, including patients with atypical 
symptoms68 (B).
In patients with GERD refractory to medical therapy, 
where gastric acid production is small (< 1 mEq/hour), 
about 50%  have esophageal pH < 4.0 for more than 1.7% 
of the time69 (B).
RECOMMENDATIONS
Patients refractory to acid suppression, with typical or 
atypical symptoms, have non-acid reflux most of the time, 
and may benefit from surgical treatment.
In a two-year follow-up of patients with erosive GERD 
and stenosis, antireflux surgery shows a 10-fold reduction 
in the number of dilations, reduces the score of dysphagia 
in 50%, and 91.9% of patients are satisfied. 
Considering that:
Low pressures in the lower esophageal sphincter are 
related to the severity of esophagitis, and in patients with 
erosive GERD treated with PPIs for 12 months, the recur-
rence rate, when there is lower sphincter dysfunction with 
pressure < 8 mmHg, whether or not associated with dys-
motility, is respectively 38.1% and 79.5%. Surgical treat-
ment should be considered in these patients. 
There is evidence of estimated surgery benefit, with 
treatment failure reduction of 12% (NNT 8), when com-
pared to medical treatment, and rates are maintained in 
the long term (7 years). But there is also evidence of equiv-
alence for medical treatment with PPIs and laparoscopic 
surgery (Nissen), with 93% and 90% of patients remaining 
in symptom remission for 3 years, respectively. 
In the long term, surgery reduces the risk of esophagitis 
by 44% (NNT: 2), and of Barrett’s esophagus and dysplasia, 
when compared to PPI therapy. In seven years of follow-
up, surgery may benefit patients with GERD (erosive or 
non-erosive) who had partial response to PPIs, especially 
in relation to quality of life. However, after 2.5 years, 37% 
of patients may be using PPIs, and, additionally, in 10 
years, many (80%) may require reoperation. Laparoscopic 
surgery enhances patient’s quality of life, even in those 
whose symptoms are adequately controlled with PPIs. 
4. AMONG PATIENTS WITH SURGICAL INDICATION, WHICH 
TECHNIQUE HAS THE BEST RESULT: TOTAL (NISSEN) OR 
PARTIAL FUNDOPLICATION (TOUPET)?
There is no difference after one year regarding the presence 
of symptoms of heartburn, regurgitation or other symptoms 
related to reflux in patients who underwent Nissen versus 
Toupet surgeries. However, the Nissen surgery increas-
es the risk of dysphagia of any degree by 18.7% (95% CI: 
6.0-31.4) – NNH: 5, and chest pain at meals by 17.1% (95% CI: 
5.7-28.5) – NNH: 6. There is no difference regarding post-
operative symptoms related to esophageal motility33 (A). 
After two postoperative years, patient satisfaction is 
equivalent between those submitted to the Nissen or Tou-
pet laparoscopic techniques. However, the Nissen sur-
gery increases the risk of dysphagia by 11.0% (95% CI: 
1.7-20.3) – NNH: 934 (A). 
There is no difference between Nissen and Toupet sur-
geries, regarding the severity of symptoms in the one-year 
postoperative period70 (A).
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In patients treated by Nissen surgery versus Toupet, 
there was no difference related to heartburn or acid regurgi-
tation control. There was also no difference in the prevalence 
of dysphagia between the two surgical techniques71 (A).
Patients who underwent the Nissen or Toupet tech-
niques are equally satisfied and reflux control is equivalent. 
However, the Nissen surgery increases the risk of dyspha-
gia, not correlated to differences in esophageal motility, in 
19.0% (95% CI: 8.1-29.9) – NNH: 572 (A).
There was no difference regarding symptom recur-
rence, dysphagia, or reflux control in the three-year post-
operative period of Nissen versus Toupet techniques73 (A).
RECOMMENDATION
There is no difference between the Nissen and Toupet sur-
gical techniques in relation to therapeutic response; how-
ever, the Nissen technique may produce more dysphagia, 
with NNH of 5 to 9, not correlated with motility. 
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